NewsBenzingaMaxCyte将以总对价1.518亿美元收购Akron BioProducts,交易方为Arcline Investment Management,其中包括1.05亿美元现金和2060万股MXCT股票,价值约2680万美元 MaxCyte将以总对价1.518亿美元收购Akron BioProducts,交易方为Arcline Investment Management,其中包括1.05亿美元现金和2060万股MXCT股票,价值约2680万美元 Benzinga 2026.11.10 11:07 (GMT+0) Open on Benzinga Other news Israeli Shipping Giant ZIM Cashes In on Surging Freight Rates, Raises Outlook UBS Maintains Buy on Home Depot, Lowers Price Target to $417 Disney Posts Upbeat Q4, Analysts Raise Price Target Citing Theme Park Resilience StoneX Maintains Buy on Bitdeer Techs, Lowers Price Target to $15 Merck Pulls Plug On Acquired Drug after Safety Review UBS Maintains Neutral on Granite Point Mortgage Tr, Lowers Price Target to $3